ID93 + GLA-SE TB Vaccine Description

AAHI’s TB vaccine ID93 + GLA-SE combines several proteins from Mycobacterium tuberculosis (Mtb), the bacterium that causes TB, into a fusion protein (“ID93”) with a proprietary immune-stimulating adjuvant (“GLA-SE”) in a freeze-dried formulation that can be stored at elevated temperatures (nearly 100 degrees Fahrenheit) for several months.

ID93 + GLA-SE Indication

ID93 + GLA-SE TB is a new vaccine that is indicated to prevent the world’s second-deadliest infectious disease.

The World Health Organization estimates that nearly 2 billion people across the globe are infected with Mtb. 

ID93 + GLA-SE Clinical Trial

The results of a Phase 1 clinical trial have been published. 

ID93 + GLA-SE elicited a stronger immune response than administration of the same vaccine using separate vials of antigen and liquid adjuvant formulation.